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ABSTRACT
Approximately 30% of the patients who fulfil the criteria of Waldenström’s 
macroglobulinemia (WM) are diagnosed while asymptomatic (indolent), and will not 
require immediate therapy. Conversely, patients with a disease-related event will be 
considered for therapy. The physiopathology of these 2 groups remains unclear, and 
the mechanisms of progression from indolent to symptomatic WM have yet to be fully 
understood. Seventeen patients diagnosed with WM were included in this study, 8 
asymptomatic WM (A-WM) and 9 symptomatic WM (S-WM). A differential analysis was 
performed on a first series of 11 patients and identified 48 genes whose expression 
separated samples from A- to S-WM. This gene signature was then confirmed on a 
second independent validation set of 6 WM. Within this expression profile, BACH2, 
a B-cell transcription factor known to be a tumor suppressor gene, was found to be 
over-expressed in A-MW relatively to S-MW. We specifically over-expressed BACH2 in 
a WM-related cell line and observed a significant reduction of the clonogenic activity. 
To the best of our knowledge, we report for the first time a specific gene expression 
signature that differentiates A-WM and S-WM. Within this expression profile, BACH2 
was identified as a candidate gene that may help to understand better the behavior 
of tumor cells in indolent WM.
INTRODUCTION
Waldenström’s macroglobulinemia (WM), a rare 
lymphoproliferative disorder characterized by bone 
marrow (BM) infiltration of lymphoplasmacytic cells 
associated with serum IgM paraprotein [1], has various 
clinical presentations. Mainly, WM is characterized with 
either symptomatic (S-WM) or asymptomatic (A-WM also 
called smoldering or indolent WM) features, according 
to the presence or absence of features attributable to 
tumor infiltration and/or attributable to the monoclonal 
protein [2]. The exact incidence rate of A-WM is unknown 
as many patients are possibly undiagnosed, and one might 
consider it represents the majority of WM [3], but the 
consequence for the patients is remarkable as A-WM 
will not require immediate therapy sometimes for years. 
Conversely, patients with WM disease-related events will 
be considered for therapy [4]. 
The long lasting indolent profile is not specific to 
WM, and is observed virtually in all B-cell non Hodgkin 
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low grade lymphoma subtypes. Understanding the key 
physiopathological mechanisms that protect tumor cells 
from progression towards aggressive/symptomatic 
disease might be a target for therapy in the very near 
future. Although progress was made in recent years to 
understand the pathogenesis of WM, very little is known 
about differences between A-WM and S-WM, and the 
mechanisms of progression from A-WM to S-WM have 
yet to be understood. Gene expression profiling has been 
shown to identify specific signature allowing clinical 
aggressiveness stratification in myeloma [5, 6] and in 
follicular lymphoma [7]. 
We therefore hypothesized that a gene signature 
that differentiates S-WM from A-WM could be identified. 
The purpose of this study was to find pathways and genes 
from this gene signature that will help better understand 
the underlying mechanisms that differentiate S-WM from 
A-WM.
RESULTS
A-WM and S-WM display different gene 
expression profile-based signatures
We first studied a set of 11 patients (5 A-WM and 6 
S-WM) with a high-throughput assay-based comprehensive 
approach. The differential analysis identified 82 probes 
corresponding to 48 genes whose patterns of expression 
resulting from using an unsupervised classification were 
able to differentiate samples from A-WM and S-WM 
(Figure 1) The 48 genes are listed in Supplementary Data 
Table 1.
Validation of the 48 genes-based signature on an 
independent set of patients
We sought to validate the 48 genes-based signature 
obtained with the first set of 11 patients on an independent 
set of 6 patients with WM. For this supervised classification 
the objective was to study whether the A-WM and S-WM 
would be correctly identified and categorized using the 
48 genes-based signature profile. Our gene expression-
profiling-based signature was overall able to classify 
accurately 94% of the 17 WM patients, including the 
6 WM of an independent validation set (Figure 2).
Pathway analysis of in the signature
We then reviewed the literature and sought for 
specific pathways involved in the difference between 
A-WM and S-WM using Ingenuity® software, on the 48 
genes independently of the fold-changes. The pathway 
analysis identified three networks: the B cell differentiation 
and activation pathway, the PI3K/AKT pathway and the 
microenvironment interactions pathways (Supplementary 
Data Table 2). Following the review of the literature, 3 
genes appeared of key interest: BACH2, CIITA and PTEN. 
BACH2 is a B-cell-specific transcription factor known to 
be a tumor suppressor gene [8]. CIITA acts as a positive 
regulator of class II major histocompatibility complex gene 
transcription [9], BACH2 increases the expression of CIITA 
through PRDM1. PTEN functions as a tumor suppressor by 
negatively regulating AKT1 signaling, a pathway involved 
in WM [10]. We then sought to confirm the transcriptional 
dysregulation of these 3 genes on patients with WM, 3 
A-WM and 4 S-WM, by qRT-PCR (Figure 3).
Genomic alteration of BACH2
In order to study further the mechanisms of 
deregulation of BACH2 in A-WM and S-WM, we 
conducted a genome wide SNP array study on 14 out of 
the 17 WM included in this study. BACH2 gene is located 
on the 6q15 locus. Among those 14 patients, 8 (4 A-WM 
and 4 S-WM) demonstrated a deletion of long arm of 
chromosome 6 (del6q), the most frequent chromosomal 
abnormality in WM, seen in approximately 50% of WM. 
Interestingly, we noticed that 3 out of the 4 S-WM with 
del6q had the 6q15 locus altered, whereas 3 out of 4 of the 
A-WM had a del6q preserving the 6q15 region (Figure 4).
BACH2 involved in clonogenic activity in A-WM
As mentioned above, we gave a special interest 
to BACH2 following ingenuity pathway analysis and 
literature review. In our study, BACH2 expression was 
increased in indolent WM relative to symptomatic WM, 
and thus we sought to reproduce in vitro the two 
asymptomatic and symptomatic WM profile through the 
study of the consequences of BACH2 deregulation on 
a WM cell-line. Of interest, we noticed that BCWM1 
was the most proliferative WM cell line (as compared 
to MWCL1 for example), in vitro. We first specifically 
over-expressed BACH2 in BCWM1, as presented in panel 
A and B of Figure 5. We then studied viability and cell 
growth. We did not observe any difference between wild 
type BCWM1 and BACH2 high engineered BCWM1 
(data not shown). We then focused on studying the 
clonogenic activity according to the level of BACH2 
expression, another major phenomenon and key feature of 
tumorigenesis. As shown on Figure 5C, we noticed that the 
clonogenic activity was significantly reduced in BACH2 
high engineered cell lines.
DISCUSSION
We have identified a specific gene expression 
signature of 48 genes that differentiates A-WM and 
S-WM, validated on an independent set of patients. 
Some genes appeared of key interest to explain the 
differences observed between A-WM and S-WM. BACH2 
is a B-cell transcription factor known to act as a tumor 
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Figure 1: GEP identifies a signature that allows to differentiate A-WM from S-WM. Gene expression data were normalized 
using the Robust Multi-array Average (RMA) algorithm. Then we performed differential analysis on a first series of 11 patients; 82 probes 
(corresponding to 48 genes) were significantly identified. The heatmap shows the spectrum of normalized expression values with a Z-score: 
red indicates a high level of mRNA expression and green indicates a low level of expression. Each row represents one of the 82 probes 
and each column a WM sample. In this unsupervised classification, patients with A-WM clustered separately from patients with S-WM.
Figure 2: Correlation plot of the transcriptional profile for A-WM and S-WM. The correlation coefficients for each of the 
WM samples with the average expression of the 82 probes in either A-WM or S-WM samples were calculated and are shown on the vertical 
axis and horizontal axis, respectively. The line of equal correlation was chosen as threshold. Patients positioned above the threshold were 
classified as A-WM; patients below the threshold were classified as S-WM. The blue dots correspond to the A-WM, the yellow ones to the 
S-WM. The circles correspond to the first 11 patients and the triangles to the 6 patients from the independent set.
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suppressor gene. CIITA is part of the same signaling 
pathway as BACH2; BACH2 represses BLIMP1 which 
represses CIITA. Otherwise, it was demonstrated that 
primary WM cells present a constitutive activation of 
the PI3K/Akt pathway [10], sustained by decreased 
expression of PTEN. In our study, BACH2, CIITA and 
PTEN expression is lower in S-WM than in A-WM. The 
suppressor of cytokine signalling-6 (SOCS6) is over-
expressed in tumor cells of patients with symptomatic WM. 
In this particular case, two pathophysiological hypotheses 
are possible. First, SOCS6 could inhibit antitumor 
immunity by suppressing effects of IFN-alpha, as described 
for SOCS3 in T lymphoma [11]. On the other hand, the 
over-expression of SOCS6 could be an epiphenomenon, 
constituting a negative feedback loop in response to 
multiple cytokine stimulation experienced by aggressive 
WM tumor cells, as described for SOCS1 in chronic 
myeloproliferative disorders [12]. Other genes could have 
also been interesting candidates considering their important 
fold-change and low p-value in the differential analysis, 
the list is available in Supplementary Table 1.
One of the important findings of this study was 
the identification of BACH2 as a potential key player 
in the aggressiveness of WM tumor cells. BACH2 is a 
transcription factor that is selectively expressed in B-cells, 
abundantly expressed in B-cell early stages and turned off 
in terminally differentiated cells [13]. This protein has 
multifaceted actions in B cell development [8], from tumor 
suppressor gene to class switch recombination and somatic 
hypermutation [14]. Most importantly, BACH2-mediated 
activation of TP53 is required for elimination of pre-B 
cells that failed to productively rearrange immunoglobulin 
gene [15]. Many studies have examined the role of BACH2 
in lymphoid neoplasms in relation to its critical actions in 
the B lymphocyte development and ontogeny, particularly 
as a tumor suppressor gene [13, 16, 17]. Importantly, it was 
shown that BACH2 reduced proliferation and induced cell 
death when over-expressed in B lymphoma tumor cells 
[17], and enforced expression of BACH2 in RAJI cell line 
resulted in marked reduction of clonogenic activity [8]. 
These findings are consistent with the key functions of 
BACH2 in the lymphomagenesis, in DLBCL, but also 
Figure 3: Confirmation of the gene expression profile by RT-qPCR. Quantification of mRNA of BACH2, CIITA and PTEN was 
performed by real time qPCR against an endogenous control gene: ABL1. Histograms show relative expression values between A-WM and 
S-WM. The white histograms correspond to Asymptomatic WM, the black ones to Symptomatic WM. A statistically significant difference 
was observed on the three genes.
Figure 4: BACH2 locus alteration differs in patients with 6q deletion according to WM status. Smooth signal of copy 
number variation is shown for 4 patients with a 6q deletion (del6q). The vertical line shows the BACH2 gene location in 6q15 region. 
Examples 1 and 4 are asymptomatic patients, with a del6q preserving the 6q15 locus. Examples 2 and 3 are symptomatic patients with a 
del6q involving 6q15 locus.
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apparently in WM as we have shown, although the exact 
mechanism of action of BACH2 remains to be identified. 
BACH2 was previously mentioned in WM in two studies 
[18, 19], as part of a gene expression profile. The first study 
discriminated clonal B lymphocytes from WM and CLL, 
while the second one discriminated Waldenström’s clone 
and normal CD22+CD25− B-cells. Interestingly, the 
second study showed that BACH2 was under-expressed in 
Waldenström’s clone (clonal B-cells from IgM MGUS and 
WM patients), consistent with our findings, and provides 
additional argument for the assumption that BACH2 plays 
a tumor suppressor gene-role in WM.
It was described that the frequency of WM patients 
displaying genomic alteration (like copy-number 
alterations or loss of heterozygosity) significantly 
increased from asymptomatic to symptomatic WM 
[19, 20]. It is therefore expected that these genomic 
abnormalities might cause a significant modification of 
Figure 5: Clonogenic activity was significantly reduced in a BACH2 high engineered cell line. Expression of Bach2 
in transfectants. (A) RNA level were measured by q-RTPCR in BCWM1 cell line non transduced (WT), infected with an empty particle 
(GFP) and in several transfectants (Bach2 #1 and #2). Histograms show relative expression values. (B) Protein expression of Bach2 was 
evaluated by Western blot in the same cell lines (p < 0,003). Only the highest Bach2 expressing clone was used for the next experiments. 
(C) Methylcellulose colony formation assay was performed on BCWM1 cell line as described in Materials and methods. As a control, 
BCWM1 non transduced (WT) and infected with an empty lentiviral particle (GFP) were used. Histograms show relative concentration values.
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gene expression profile, as shown in our study for the 
first time to the best of our knowledge. Surprisingly, 
Paiva et al. [19] reported absence of difference between 
the gene expression profile of A-WM versus S-WM; 
possibly explained by the lower number of patients in their 
transcriptomic study (4 asymptomatic and 6 symptomatic). 
Furthermore, Paiva et al. used FACS-sorted cells, while 
we used immunomagnetic beads sorted cells (purity of 
sample was then confirmed by flow cytometry).
We showed that the MDR (minimal deleted region) 
of del6q seemed to differ in size for A-WM and S-WM, 
and also seemed to differ in the integration of the 
6q15 locus, where BACH2 is located. Indeed, among 
patients with del6q, we noticed that patients with S-WM 
demonstrated more frequently a del6q involving the 6q15 
locus. We therefore concluded that haploinsufficiency 
could participate in the under-expression of BACH2 in 
symptomatic WM
In our study, BACH2 expression did not seem to be 
correlated with viability and cell growth in WM, but only 
with clonogenic activity. The same data was reported in 
RAJI cell line [8]. In this study, the authors also performed 
two kinds of assays. One was to monitor growth curves, 
and the other was to monitor colony formation activity. 
The latter assay is thought to be more stringent in terms of 
cell proliferation.
Finally, these data might have therapeutic 
applications. Targeting a tumor suppressor gene is known 
to be difficult, but the BACH2 pathway could be targeted. 
For example, BACH2 represses BLIMP1. A BLIMP1 
inhibitor could possibly guide symptomatic WM cells in a 
more indolent phenotype.
We report for the first time a GEP signature allowing 
to distinguish asymptomatic from symptomatic WM. 
Using this set of data we have identified key pathways 
and genes to help further understand the mechanisms of 
progression and the physiopathology of WM. In particular, 
BACH2 expression seems to be significantly correlated 
with the phenotypic differences between asymptomatic and 
symptomatic WM. Future studies will help validate this gene 
signature and might decipher the role of BACH2 in WM.
MATERIALS AND METHODS
Patients
Seventeen patients diagnosed with WM [1] (8 
A-WM and 9 S-WM) were included in this study. Table 1 
summarizes the main characteristics of the patients. 
Patients were untreated and gave informed consent prior 
to research sampling. The median age was 70 years (range, 
61–86). Approval of this protocol was obtained from the 
local IRB of the CHRU of Lille (CSTMT043) and the 
study was conducted in accordance with the Declaration 
of Helsinki.
Conventional Cytogenetic, FISH, Immunophe-
notypic studies were available for all the patients and 
performed as previously published [20].
Cell selection
Research sampling consisted of BM samples and 
blood cells for all WM patients. T lymphocytes normal 
fraction was used as an intra-individual reference to 
distinguish acquired somatic aberrations in WM from 
germline polymorphisms. The samples were enriched for 
cell population of interest using immunomagnetic beads 
(B cell isolation kit for tumoral cells, and Pan T cell 
isolation kit, Myltenyi-Biotec, USA). The purity of 
samples was confirmed by flow cytometry on tumor 
(CD19, kappa and lambda) and normal cell fractions (CD3, 
T lymphocytes). DNA was extracted using Qui Amp kit 
(Sigma-Aldrich Co. Saint-Quentin Fallavier France). Total 
RNA was extracted using the Trizol method (Invitrogen, 
Carlsbad CA). 
Cell line and lentiviral infection
BCWM.1 cell line was used in this study. This is a 
B-cell line developed in patients with WM; BCWM.1 was 
a gift from Dr S.P. Treon from DFCI (Dana-Farber Cancer 
Institute) [21], and harboring MYD88 L265P mutation 
but no 6q deletion. Lentiviral constructs expressing 
GFP and resistance to puromycin used to generate stable 
Bach2 expressing BCWM.1 cell line (BCWM.1-Bach2) 
and empty vector (BCWM.1-GFP) were purchased from 
Applied Biological Material (ABM) Inc. (Richmond, BC). 
BCWM.1 cell line was exposed to lentiviral particles for 
6 hours at a multiplicity of infection (MOI) of 2. Two 
days after the infection, selection of the infected cells was 
done by adding puromycin to the culture medium at a 
concentration of 1 µg/mL. 
Proliferation, viability, immunoblotting and 
clonogenicity assay
Viability and cell growth were determined using the 
MTS assays, CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (Promega) and the Click-iT® EdU 
Flow Cytometry Assay kit (Invitrogen) according to the 
manufacturer’s protocol, respectively. Apoptosis was 
measured using annexin V - propidium iodide staining 
using flow cytometric analysis (Beckman Coulter, Brea, 
CA, USA). Study of mitochondrial membrane potential 
was achieved using MitoTracker Red CMXRos-Special 
Packaging® (Invitrogen). Study of caspases activity was 
performed using staining CaspaLux® (OncoImmunin, 
Gaithersburg, MD). The clonogenic activity of each 
BCWM1 clone was evaluated by methylcellulose 
culture. 500 cells were placed in 1 ml of methylcellulose 
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medium without cytokines (MethoCult H4230, Stemcell 
technologies, Vancouver, Canada) in duplicates, and 
incubated under fully humidified conditions in 35 mm 
Petri dish (Greiner Bio-One, Kremsmünster, Austria) at 
37°C in 5% CO2. Colonies were numbered on day 10. 
The following antibodies were used for immunoblotting 
on whole cell lysates: anti-BACH2 (LSBio®, Seattle, WA, 
USA) and anti-actin (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA).
Real-time quantitative reverse transcription PCR
Quantification of mRNA of BACH2, CIITA and 
PTEN was performed by real time qPCR against an 
endogenous control gene, ABL1, with correspondent 
Taqman® assays on StepOneTM Real-Time PCR System 
(Life Technologies, CA, USA). Relative expression values 
were calculated using the means of ∆ Ct (threshold cycle) 
from the triplicates and expressed as 2-DDCt. 
Single nucleotide polymorphism array analysis 
and gene expression profiling
Genome-wide detection of copy number alteration 
(CNV) and loss of heterozygosity (LOH) were available in 
13 of the 17 WM cases using the Genome-Wide Human SNP 
Array 6.0 (Affymetrix) [20]. It allows precise delineation 
of the location and size of submicroscopic chromosomal 
defects, copy-neutral LOH and germline CNVs.
Gene expression profiling (GEP) was performed 
using U133 Plus 2.0 arrays (Affymetrix, USA), that 
analyzed over 47,000 transcripts. The RNA integrity was 
assessed using 2100 Bioanalyzer (Agilent, CA, USA). 
Expression data were normalized using the Robust 
Multi-array Average (RMA) algorithm. We performed 
differential analysis on a first series of 11 patients (5 
A-WM and 6 S-WM) calculated with the ‘metaMA’ [22] 
R package (with the ‘limma’ option) in order to establish 
a gene expression profile. We then used a supervised 
classification to distinguish A-WM from S-WM as 
previously described [23]. Therewith, we validated this 
profile on an independent set of 6 patients (3 A-WM and 
3 S-WM). We then performed a pathway analysis using 
Ingenuity Pathways Analysis® (Ingenuity Systems, CA, 
USA).
Other statistical analyses
Statistical associations were assessed using Chi2 and 
Fisher exact tests. Pairwise comparisons were performed 
by Mann-Whitney test or Student’s t-test. Overall survival 
was defined as the time between diagnosis and death or the 
last follow-up. Statistics were achieved using SPSS 15.0.
Table 1: Characteristics of the patients which samples were used in this study
Patient Age* / sex MYD88 mutation Clinical status
Criteria of symptomatic 
disease M-comp at time of GEP (g/L)
GEP 
profile
6q deletion / BACH2 
deletion†
3 63/F + A-MW NA 30 A no / no
5 76/F + A-MW NA 11 A yes / yes
7 83/M + A-MW NA 37 A (ivs) uk
9 61/M + A-MW NA 15 A yes / no
25 63/F − A-MW NA 26 A (ivs) yes / no
28 63/F + A-MW NA 19 A no / no
30 68/F − A-MW NA 6 A (ivs) no / no
31 64/M + A-MW NA 20 A yes / no
1 81/M + S-MW Autoimmune hemolytic anemia 26 S (ivs) no / no
2 70/F + S-MW Central anemia 37 S yes / yes
4 69/M + S-MW Central anemia 52 S yes / yes
6 62/F − S-MW Central anemia 49 S yes / no
8 73/F + S-MW Central anemia 50 A (ivs) uk
12 86/M + S-MW Adenopathies 23 S no / no
18 66/M + S-MW Central anemia and cryoglobulinemia 19 S (ivs) uk
20 65/M + S-MW Pancytopenia 12 S no / no
27 78/M + S-MW Central anemia 25 S yes / yes
Abbreviations: M: male, F: female, A-WM: asymptomatic WM, S-WM: symptomatic WM, ivs: independent validation set, 
uk: unknown, M-comp: monoclonal-component. 
*At the time of diagnosis; †: by SNP.
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